Sen-Jam Pharmaceutical isn’t your ordinary biotech company.
It’s out to help those who are suffering from cancer, diabetes, respiratory infections, heart disease, and arthritis — all by focusing on one particular problem.
That problem is inflammation. Perhaps surprisingly, eighty percent of all major human diseases are a result of inflammation. And 150 million Americans suffer from it.
By repurposing FDA-approved small molecules, Sen-Jam is developing innovative, proprietary, potent anti-inflammatory medicines. As the company says, its approach to treating inflammation is the biggest pharmacological advancement since aspirin was invented 125 years ago.
Sen-Jam is led by scientific advisors with experience at the Mayo Clinic, Boston Medical Clinic, Harvard School of Public Health, and Cornell University.